Piper Jaffray analyst Danielle Brill reiterated an Overweight rating and $64 price target on Zogenix after hosting an epilepsy panel and fireside chat with Zogenix CEO Stephen Farr this week. Brill said that 2020 is looking to be a "transformational year" for the company with Fintepla Pivotal Phase 3 Lennox-Gastaut Syndrome data reading in the first quarter and potential approval/commercial launch for Dravet Syndrome. The analyst said she discussed the prospects for the drug during the firm's expert panel and feedback continues to be "positive," adding that she believes Fintepla will be approved for DS and sees the launch being "successful." Brill added that she is optimistic that the Phase 3 LGS trial will be "positive" and the drug will be "impactful" for that indication as well.